ClariVest Asset Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

ClariVest Asset Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-311	Closed	-$305K	–	758
2016 Q4	$305K	Buy	311 +24	+8%	+$27.4K	0.01%	451
2016 Q3	$387K	Buy	287 +4	+1%	+$4.51K	0.01%	415
2016 Q2	$247K	Buy	283 +103	+57%	+$136K	0.01%	455
2016 Q1	$251K	Buy	180 +35	+24%	+$49.8K	0.01%	438
2015 Q4	$267K	Buy	145 +67	+86%	+$134K	0.01%	417
2015 Q3	$152K	Hold	78	–	–	﹤0.01%	448
2015 Q2	$176K	Buy	+78	New	+$183K	0.01%	419

Other funds holding TCON

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClariVest Asset Management's TCON Position: Q1 2017 in Review

ClariVest Asset Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2017, closing a stake of 311 shares — an estimated $305K sold.

ClariVest Asset Management first reported a position in TCON in Q2 2015 and held it in 7 quarters. The position peaked at $387K in Q3 2016. 22 funds tracked by Wall St. Rank hold TCON as of Q1 2017.

ClariVest Asset Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
ClariVest Asset Management sold 311 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2017, an estimated $305K.
ClariVest Asset Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2015 and held it in 7 quarters.
ClariVest Asset Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $387K in Q3 2016.
22 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2017.

Based on ClariVest Asset Management's 13F filing for Q1 2017, filed 11 May 2017.